Sitravatinib
Lung Diseases
Sarah GoldbergSmall moleculePhase 2Active
CCC
49/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 34/ 100
- Competitive Position
- 81/ 100
Competitive context
24 Active assets in the Lung Diseases cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Jiangmen Central Hospital | Phase 3 | BB |
Ivacaftor University of British Columbia | Phase 3 | BB |
Theophylline NCIC Clinical Trials Group | Phase 3 | BB |
Lumacaftor Vertex Pharmaceuticals Incorporated | Phase 3 | BB |
Pralsetinib, trans- Hoffmann-La Roche | Phase 3 | B |
View all 50 →
Same molecule, other indications
Sitravatinib is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →